Pregnant women who use antidepressants to manage depression should talk with their doctors for a personalized recommendation on how the antidepressants may affect the pregnancy.
Depression and other mental health conditions can be serious, and many women need to take medications during pregnancy to appropriately manage their symptoms. Abruptly stopping the use of medications to treat these conditions can have serious consequences.
“Women should talk to a healthcare provider to make informed decisions based on their individual situation. Of course, ideally women would discuss treatment options for depression and other health conditions before pregnancy,” said Jennita Reefhuis, MD, epidemiologist with CDC’s National Center on Birth Defects and Developmental Disabilities.
Related:FDA defers to docs in use of pain therapies for pregnant women
According to Dr Reefhuis, there are 5 important points to remember when using antidepressants during pregnancy:
In a CDC-funded study published in The BMJ, Dr Reffhuis and researchers assessed several previously reported links between SSRI use and birth defects using more recent data and results from previously published independent studies. Researchers found some birth defects occur about 2 or 3 times more frequently among babies born to women who took certain SSRI medications, such as fluoxetine and paroxetine, early in pregnancy.
NEXT: Discuss medication before pregnancy
In this study, the researchers used an analysis strategy that allowed us to combine results from the published literature with more than 12 years of data from the National Birth Defects Prevention Study, a large study in the United States aimed to identify risk factors for birth defects. They compared women who took an SSRI in early pregnancy and who had a baby with a birth defect, with women taking the same SSRI who had live born babies without a major birth defect.
Related:FDA antidepressant warnings may have lead to more teen suicide attempts: Study
“However, it is important to keep in mind that even for these confirmed links, the risk to an individual woman who is taking this medication is still small. Reassuringly, we found that we could not replicate five earlier reported links with birth defects for sertraline, the most commonly used SSRI in our US study population,” Dr Reefhuis said.
The information in this study should be helpful in guiding formulary managers to the best treatment options for depression and other mental health disorders both before and during early pregnancy, she said.
“The best time to discuss the safety of medication use is before pregnancy, because early pregnancy is a critical time for a baby’s organs to develop,” she said. “These findings can be used to help minimize the risk of major birth defects while providing treatment to manage a woman’s symptoms. When treating women who are already pregnant, it is important for healthcare providers to discuss the risk and benefits of antidepressants as well as the safest options available based on their patient’s individual situation.”
Read next: Lutera is the latest birth control recall
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More